Cure Today21 小时
Neoadjuvant Tyvyt With Chemo Improve Responses in Resectable, Locally Advanced ESCC
In resectable, locally advanced esophageal squamous cell carcinoma, neoadjuvant Tyvyt plus chemoradiotherapy led to an ...
Pharm Exec6 天
ImmunityBio, BeiGene Strike Deal to Conduct Phase III Trial for Tislelizumab, Anktiva in ...
The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...
GlobalData on MSN6 天
ImmunityBio and BeiGene partner on Phase III trial of NSCLC treatment combo
The trial is anticipated to enrol 462 subjects and aims to confirm the safety and efficacy of the combination.
Armed robbery in Revesby1 天
IXCHIQ Vaccine Approved for Chikungunya Protection
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 4 February 2025, approved the vaccine chikungunya vaccine (live) (brand name ...
Le Lézard2 天
Pfizer's BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival ...
Pfizer Inc. today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib) in combination with cetuximab ...
Armed robbery in Revesby1 天
Pfizer's BRAFTOVI Regimen Boosts Survival in Phase 3 Trial
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...
Too Old to Operate5 天
Severe Risk in HM Posed by Community‐Acquired Respiratory Viral Infections
Community‐acquired respiratory viral infections are a severe risk for patients with hematological malignancies, particularly those undergoing active treatment.